Companies › Mundipharma Research
1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rezafungin Acetate 1,3-beta-D-glucan synthase inhibitor | FKS1 | Phase 2 | Pneumocystis Pneumonia; Chronic Pulmonary Aspergillosis | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05835479 | Rezafungin Acetate | Phase 2 | Pneumocystis Pneumonia | Respiratory | May 2025 |
| NCT06794554 | Rezafungin Acetate | Phase 2 | Chronic Pulmonary Aspergillosis | Infectious disease | Nov 2026 |
Thirty Respiratory Joincare Pharmaceutical Group Industry Shanghai Yidian Pharmaceutical Technology Development Materia Medica Holding Hyundai Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.